Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. The 2024 Baron Ver Heyden de Lancey Lecture on Medico-Legal Studies was delivered by Professor Sir Jonathan Montgomery of University College London on 21 March 2024, and was entitled "Medicine and the Rule of Law". For more information about the Baron Ver Heyden de Lancey Lecture series, please see: http://www.lml.law.cam.ac.uk/events/vhdl-events

Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. The 2024 Baron Ver Heyden de Lancey Lecture on Medico-Legal Studies was delivered by Professor Sir Jonathan Montgomery of University College London on 21 March 2024, and was entitled "Medicine and the Rule of Law". For more information about the Baron Ver Heyden de Lancey Lecture series, please see: http://www.lml.law.cam.ac.uk/events/vhdl-events This entry provides an audio source for iTunes.

The 2023 Baron Ver Heyden de Lancey Lecture on Medico-Legal Studies was delivered by Professor Emily Jackson (London School of Economics) on 16 March 2023. Emily Jackson is Professor of Law at the London School of Economics. She is a member of the British Medical Association Medical Ethics Committee, and until 2012, she was Deputy Chair of the Human Fertilisation and Embryology Authority. From 2014-2017, she was a Judicial Appointments Commissioner. She is a Fellow of the British Academy, and in 2017 was awarded an OBE for services to higher education. Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. For more information about the Baron Ver Heyden de Lancey Lecture series, please see http://www.lml.law.cam.ac.uk/events/vhdl-events

The 2023 Baron Ver Heyden de Lancey Lecture on Medico-Legal Studies was delivered by Professor Emily Jackson (London School of Economics) on 16 March 2023. Emily Jackson is Professor of Law at the London School of Economics. She is a member of the British Medical Association Medical Ethics Committee, and until 2012, she was Deputy Chair of the Human Fertilisation and Embryology Authority. From 2014-2017, she was a Judicial Appointments Commissioner. She is a Fellow of the British Academy, and in 2017 was awarded an OBE for services to higher education. Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. For more information about the Baron Ver Heyden de Lancey Lecture series, please see http://www.lml.law.cam.ac.uk/events/vhdl-events This item provides an audio entry for iTunes.

Regenerative medicine seeks to regrow, repair, or replace damaged tissues. Current regenerative technologies include the bio-engineering of organs and tissues, cell reprogramming, and gene editing. Such interventions are significant not only for present-day patients, but also for future generations. They challenge the concept of the self as ‘biologically finite’ or ‘genetically determined’ and blur traditional distinctions between therapy and enhancement and between humans, animals, and things. Given the ways in which regenerative medicine blurs socially-significant boundaries, the ethical and legal obligations of clinicians, researchers, funders, and governments are fluid and uncertain. For example, it is unclear whether present policies governing the use of regenerative technologies offer sufficient safeguards, even if access is limited to patients with conditions deemed sufficiently serious to justify the risks. This talk explores whether international human rights law might require governments to identify, monitor, and support translational pathways that would provide broad, equitable access to the benefits of regenerative medicine, or whether international human rights law requires a more controlled approach because of the potential social implications. With regenerative medicine's great potential, the welfare of current and future generations is at stake. We must collectively ask ourselves how best to secure a desirable clinical future for present day and future generations. About the Speaker: Bartha Maria Knoppers is Full Professor, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy at McGill University. Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. For more information about the Baron Ver Heyden de Lancey Lecture series, please see http://www.lml.law.cam.ac.uk/events/vhdl-events This entry provides an audio source for iTunes.

Regenerative medicine seeks to regrow, repair, or replace damaged tissues. Current regenerative technologies include the bio-engineering of organs and tissues, cell reprogramming, and gene editing. Such interventions are significant not only for present-day patients, but also for future generations. They challenge the concept of the self as ‘biologically finite’ or ‘genetically determined’ and blur traditional distinctions between therapy and enhancement and between humans, animals, and things. Given the ways in which regenerative medicine blurs socially-significant boundaries, the ethical and legal obligations of clinicians, researchers, funders, and governments are fluid and uncertain. For example, it is unclear whether present policies governing the use of regenerative technologies offer sufficient safeguards, even if access is limited to patients with conditions deemed sufficiently serious to justify the risks. This talk explores whether international human rights law might require governments to identify, monitor, and support translational pathways that would provide broad, equitable access to the benefits of regenerative medicine, or whether international human rights law requires a more controlled approach because of the potential social implications. With regenerative medicine's great potential, the welfare of current and future generations is at stake. We must collectively ask ourselves how best to secure a desirable clinical future for present day and future generations. About the Speaker: Bartha Maria Knoppers is Full Professor, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy at McGill University. Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. For more information about the Baron Ver Heyden de Lancey Lecture series, please see http://www.lml.law.cam.ac.uk/events/vhdl-events

How do we ensure a level playing field in sport given natural variations in human biology? When athletes’ biological levels differ from the norm set by their federation for a given sport, what is to be done? For example, is it fair to force female athletes to take testosterone-lowering drugs to be eligible to compete? In 2018, the International Association for Athletic Federations (IAAF) enacted regulations that prevent female athletes with naturally high levels of testosterone from competing in some athletics events. The validity of these regulations was challenged by South African Olympian Caster Semenya and Athletics South Africa, however the Court of Arbitration for Sport upheld the rules in 2019. As a result, athletes like Semenya need to take testosterone lowering medication in order to compete. These decisions by the IAAF and the Court were highly controversial. The World Medical Association, for example, demanded the immediate withdrawal of the regulations, arguing that they discriminate based on the genetic variation of female athletes and that it violates the principles of medical ethics for physicians to prescribe a potentially harmful treatment if the purpose is not therapeutic. On 25 February 2021, Semenya announced that she was taking her case to the European Court of Human Rights. Is it justifiable for the IAAF to require that an athlete take testosterone-lowering drugs to alter a natural trait that does not pose a medical problem? In what ways, if any, can high testosterone be considered different from other genetically-based traits that provide a performance advantage in sport, but that are not considered unfair and subject to regulation? Dr Silvia Camporesi will explore these and related questions about the law and ethics of regulating and determining fairness in sport. About the Speaker: Dr Silvia Camporesi is a tenured Senior Lecturer in the Department of Global Health & Social Medicine at King's College London, where she is the Director of the MSc in Bioethics & Society. In her research, Silvia merges her personal interest in track and field (she is a former middle-distance runner) with her professional interests in ethics and sport. Silvia has worked on the eligibility of female athletes with hyperandrogenism to compete in the female category since 2009, and was appointed to the World Anti-Doping Agency's Ethics Advisory Group in January 2021.

How do we ensure a level playing field in sport given natural variations in human biology? When athletes’ biological levels differ from the norm set by their federation for a given sport, what is to be done? For example, is it fair to force female athletes to take testosterone-lowering drugs to be eligible to compete? In 2018, the International Association for Athletic Federations (IAAF) enacted regulations that prevent female athletes with naturally high levels of testosterone from competing in some athletics events. The validity of these regulations was challenged by South African Olympian Caster Semenya and Athletics South Africa, however the Court of Arbitration for Sport upheld the rules in 2019. As a result, athletes like Semenya need to take testosterone lowering medication in order to compete. These decisions by the IAAF and the Court were highly controversial. The World Medical Association, for example, demanded the immediate withdrawal of the regulations, arguing that they discriminate based on the genetic variation of female athletes and that it violates the principles of medical ethics for physicians to prescribe a potentially harmful treatment if the purpose is not therapeutic. On 25 February 2021, Semenya announced that she was taking her case to the European Court of Human Rights. Is it justifiable for the IAAF to require that an athlete take testosterone-lowering drugs to alter a natural trait that does not pose a medical problem? In what ways, if any, can high testosterone be considered different from other genetically-based traits that provide a performance advantage in sport, but that are not considered unfair and subject to regulation? Dr Silvia Camporesi will explore these and related questions about the law and ethics of regulating and determining fairness in sport. About the Speaker: Dr Silvia Camporesi is a tenured Senior Lecturer in the Department of Global Health & Social Medicine at King's College London, where she is the Director of the MSc in Bioethics & Society. In her research, Silvia merges her personal interest in track and field (she is a former middle-distance runner) with her professional interests in ethics and sport. Silvia has worked on the eligibility of female athletes with hyperandrogenism to compete in the female category since 2009, and was appointed to the World Anti-Doping Agency's Ethics Advisory Group in January 2021.

If doctors believe that they might be able to save a dying child, should the parents have the freedom to pursue this treatment? If a court decides that the treatment is not in the child's best interests, should it have unlimited authority to intervene? When deciding what care a child receives, should the wishes of the parents be given any weight? These questions raise complex issues about the boundaries of court power, and how far the state can intervene in what might be considered private, family decisions. They demand we consider the extent to which we give parents the freedom to decide about their children and when this might yield to consideration about the child's welfare. Who knows best? The court? The doctors? The parents? In this talk, Dr Imogen Goold (University of Oxford, Faculty of Law) explores these and related questions about the scope of parental and judicial power.

If doctors believe that they might be able to save a dying child, should the parents have the freedom to pursue this treatment? If a court decides that the treatment is not in the child's best interests, should it have unlimited authority to intervene? When deciding what care a child receives, should the wishes of the parents be given any weight? These questions raise complex issues about the boundaries of court power, and how far the state can intervene in what might be considered private, family decisions. They demand we consider the extent to which we give parents the freedom to decide about their children and when this might yield to consideration about the child's welfare. Who knows best? The court? The doctors? The parents? In this talk, Dr Imogen Goold (University of Oxford, Faculty of Law) explores these and related questions about the scope of parental and judicial power.

Baron Cornelius Ver Heyden de Lancey (1889-1984) was a wealthy and public-spirited Dutchman who at different times in his life was a dentist, doctor, surgeon, barrister and art historian. In 1970 he created the De Lancey and De La Hanty Foundation, to promote studies in medico-legal topics. The Foundation generously gave Cambridge the Ver Heyden de Lancey Fund, which since 1996 has funded occasional public lectures on medico-legal issues of current interest. The 2018 Baron Ver Heyden de Lancey Lecture on Medico-Legal Studies was delivered by Professor Glenn Cohen is a Professor of Law at Harvard University, on 9 March 2018, and was entitled "Parenthood Disrupted(?) Dilemmas of Reproductive Technologies". Glenn Cohen is a Professor of Law at Harvard University, and one of the world's leading experts on the intersection of bioethics and the law. His award-winning research has appeared in the top legal, ethical and medical journals, and he is regularly cited in national news media. He has authored and edited several books, including Patients with Passports, Specimen Science, and Identified versus Statistical Lives. Prior to receiving tenure at Harvard, he served as a law clerk on a U.S. federal Court of Appeals and as an appellate lawyer for the U.S. Department of Justice. In his spare time, he still litigates, most recently having authored amicus briefs for U.S. Supreme Court cases on the patentability of human genes and abortion rights. A gallery of photographs from the event is available at https://1drv.ms/f/s!Au0Tn35SqSa2gYkI0p2cjZU0Jvv9mQ This event is kindly sponsored by the Ver Heyden de Lancey Fund, and organised by the Centre for Law, Medicine and Life Sciences, in collaboration with Cambridge Family Law. For more information about the Baron Ver Heyden de Lancey Lecture series, please see http://www.lml.law.cam.ac.uk/events/vhdl-events